Therapy selection should be individualized and based on the patient’s specific needs and global related health risks. 

In addition,  for the management of these cases and the individual risk evaluation, specific knowledge is necessary about the particular pathologic entity and the possible contraceptive action.

In fact,  the superficial evaluation can lead to refuse a safe contraceptive method when suitable,  or to prescribe a hormonal contraceptive when hazardous.  These circumstances, at   the   worst,  could   be   object   of   serious   legal   proceedings.

Surveillance of the user’s health and follow-up are needed.  Consequently,  an accurate contraceptive counselling, a good experience in this field and an optimal knowledge of each contraceptive method,  together with its potential adverse effects, are mandatory for a modern contraceptive strategy. 

—
Rosa Sabatini and Giuseppe Loverro
Dept.Obstetrics and Gynecology,
General Hospital Policlinico-University of Bari, Italy

REFERENCES
[1]  Mall-Haefeli,  M.  (1980).  Internal   medecine   problems   regarding contraception. Part 1. Schweiz Med.Wochenschr, 110(36), 1314-9.
[2]  Grady,  W.R.,Billy,  J.O.,  Klepinger,  D.H.  (2002). Contraceptive method switching in the United States. Perspect. Sex Reprod. Health, 34(3), 135-45. 
[3]  Sabatini,  R.,Cagiano,  R.  (2006). Comparison profiles of cycle control, side-effects   and   sexual   satisfaction   of   three   hormonal contraceptives. Contraception, 74,220-223
[4]  Belaisch, J., Eliakim, V. (1993). Third generation progestagens. Contracept. Fertil. Sex (Paris), 21(4), 287-93. 
[5]  Gerstman,  B.B.,  Piper,  J.M.,  Tomita,  D.K.,  Ferguson,  W.J.,  Stadel,  B.V., Lundin, E.E. (1991). Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am.J. Epidemiol, 133, 32-37.
[6]  Kemmeren,  J.M.,  Algra,  A., Grobbee,  D.E.  (2001).  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.  Br.Med.J, 323,131-134. 
[7]  Geist,  R.,  Beyth,  Y.  Extended   cycle   oral   contraceptives. Harefuah, 2007;146(10): 781-4,813. 
[8]  Haile,  R.W., Thoma,  D.C.,  McGuire,  V.,  Felberg,  A.,  John,  E.M.,  Milne, R.L., Hopper, J.L. et al. (2006). BRCA1 and BRCA2 mutation carriers, oral contraceptives use, and breast cancer before age 50. Cancer Epidemiol. Biomarker Prev, 15(10), 1863-70.
[9]  Brohet,  R.M., Goldgar,  D.E.,  Easton,  D.F.,  Antoniou,  A.C.,  Andrieu,  N., Chang-Claude, J. et al. (2007). Oral contraceptives and breast cancer in the international   BRCA 1/2   carrier   cohort   study: a   report   from EMBRACE, GENEPSO, GEO-HEBON   and   the   IBCCS   Collaborating Group. J.Clin.Oncol, 25(25), 3831-6. 
[10]  Sabatini,  R., Orsini,  G., Cagiano R.,  Loverro G.  (2007).  Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception, 76, 342-347. 
[11]  Garden,  A.S.  (2003).  Teenage pregnancy.  In Amy JJ ed,. Paediatric and adolescent gynaecology. Amsterdam. Elsevier, 263-70. 
[12]  Bloemenkamp,  K.W.,  Rosendaal,  F.R.,  Helmerhorst,  F.M.,  Buller, H.R., Vandenbroucke,  J.P.  (1995).  Enhancement   by   factor   V   Leiden mutation   of   risk   of   deep–vein   thrombosis   associated   with   oral contraceptives containing a third-generation progestagens. Lancet, 346, 1593-6.
[13]  Comp, P.C., Rsmonm C.T. (1984). Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N.  Engl. J. Med,  311,1525-1528).
[14]  Schwartz,  S.M., Siscovick,  D.S.,  Longstreth,  W.T.,  Psaty,  B.M.,  Beverly, R.K.,  Raghunathan,  T.E.,  Lin,  D.  (1997).  Use   of   Low–Dose   Oral Contraceptives and Stroke in Young Women.  Annals Int. Med,  Vol.127 Issue 8(part 1), 596-603. 
[15]  Shaaban,  M.M.  (1996). The perimenopause and contraception. Maturitas, 23(2), 181-92
[16]  Speroff, L., Sulak, P.J. (1995). Contraception in the later reproductive years: a valid aspect of preventive health care. Dialogues Contracept, 4(5), 1-4. 
[17]  Shen,  Q.,  Lin,  D.,  Jiang,  X.,  Li,  H.,  Zhang,  Z.  (1994).  Blood pressure changes and hormonal contraceptives.Contraception, 50(2), 131-41. 
[18]  Dennerstein,  L.,  Duldey,  E.C.,  Hopper,  J.C.,  Burger,  H.  (1997). Sexuality,hormones and the menopausal transition.Maturitas, 26, 83-93.
[19]  Petitti,  D.B.,  Sidney,  S., Quesenberry,  C.P.  (1998).  Oral contraceptive useand myocardial infarction. Contraception, 57, 143-155. 
[20]  Parkin,  L.,  Skegg,  D.C., Wilson,  M.et al.  (2000).Oral contraceptives and fatal Pulmonary embolism. Lancet, 355, 2133-34, 
[21]  Jick, H., Jick, S.S., Gurewich, V., Myers, M.W., Vasilakis, C. (1995). Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.Lancet, 346, 1589-93. 
[22]  Petersen,  K.R.  (2002). Pharmacodynamic effects of oral contraceptives steroid on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan.Med. Bull, 49(1), 43-60). 
[23]  Sondheimer S.J.  (1991). Update on the methabolic effects of steroidal contraceptives. Endocrinol. Metab. Clin. North Am, 20(4), 911-23